EE500 Cost-Effectiveness Analysis of Cemiplimab As Second-Line Therapy for Recurrent Cervical Cancer in Japan
Jun 1, 2023, 00:00
10.1016/j.jval.2023.03.2479
https://www.valueinhealthjournal.com/article/S1098-3015(23)02669-4/fulltext
Title :
EE500 Cost-Effectiveness Analysis of Cemiplimab As Second-Line Therapy for Recurrent Cervical Cancer in Japan
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)02669-4&doi=10.1016/j.jval.2023.03.2479
First page :
Section Title :
Open access? :
No
Section Order :
10269